|
Synonyms: Monurol® | phosphomycin | phosphonomycin | Veramina®
fosfomycin is an approved drug (UK (1994), FDA (1996))
Compound class:
Natural product
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Fosfomycin can be used to treat uncomplicated urinary tract infections (UTIs e.g. cystitis) and prostatitis due to susceptible strains of Escherichia coli and Enterococcus faecalis for which it is generally given as a single oral dose as fosfomycin tromethamine. The drug can be administered as intravenous infusion (as the disodium salt), but this parenteral formulation is not available in the US. Fosfomycin is unsuitable for sustained therapy of severe infections as bacterial resistance can develop during therapy. Despite this i.v. fosfomycin (ZTI-01) is being evaluated in clinical studies for treatment of complicated UTIs [4] (NCT02753946). Under EMA jurisdiction, fosfomycin was granted orphan designation (in 2015) in a fixed-dose combination of fosfomycin disodium and tobramycin for the treatment of cystic fibrosis patients. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
| Fosfomycin inhibits bacterial cell wall biogenesis by inactivating the peptidoglycan biosynthetic enzyme UDP-N-acetylglucosamine-3-enolpyruvyl transferase, (MurA) [3]. |
External links ![]() |
|
For extended ADME data see the following: Drugs.com |